In a study sequencing 336 pancreatic cancer specimens, potentially actionable targets were identified in 26% of cases, including alterations in ERBB2, BRCA1 or BRCA2, BRAFV600E, ROS1, and ALK1 [118]. This evidence concerns the gene ROS1 and familial pancreatic carcinoma.